Cargando…

Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study

BACKGROUND: Type 2 diabetes is associated with both impaired insulin action at target tissues and impaired insulin secretion in pancreatic beta cells. Mitochondrial dysfunction may play a role in both insulin resistance and impaired insulin secretion. Plasma creatine has been proposed as a potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Post, Adrian, Groothof, Dion, Schutten, Joëlle C., Flores‐Guerrero, Jose L., Swarte, J. Casper, Douwes, Rianne M., Kema, Ido P., de Boer, Rudolf A., Garcia, Erwin, Connelly, Marge A., Wallimann, Theo, Dullaart, Robin P. F., Franssen, Casper F. M., Bakker, Stephan J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048485/
https://www.ncbi.nlm.nih.gov/pubmed/33348429
http://dx.doi.org/10.1111/cen.14396
_version_ 1783679230908825600
author Post, Adrian
Groothof, Dion
Schutten, Joëlle C.
Flores‐Guerrero, Jose L.
Swarte, J. Casper
Douwes, Rianne M.
Kema, Ido P.
de Boer, Rudolf A.
Garcia, Erwin
Connelly, Marge A.
Wallimann, Theo
Dullaart, Robin P. F.
Franssen, Casper F. M.
Bakker, Stephan J. L.
author_facet Post, Adrian
Groothof, Dion
Schutten, Joëlle C.
Flores‐Guerrero, Jose L.
Swarte, J. Casper
Douwes, Rianne M.
Kema, Ido P.
de Boer, Rudolf A.
Garcia, Erwin
Connelly, Marge A.
Wallimann, Theo
Dullaart, Robin P. F.
Franssen, Casper F. M.
Bakker, Stephan J. L.
author_sort Post, Adrian
collection PubMed
description BACKGROUND: Type 2 diabetes is associated with both impaired insulin action at target tissues and impaired insulin secretion in pancreatic beta cells. Mitochondrial dysfunction may play a role in both insulin resistance and impaired insulin secretion. Plasma creatine has been proposed as a potential marker for mitochondrial dysfunction. We aimed to investigate the association between plasma creatine and incident type 2 diabetes. METHODS: We measured fasting plasma creatine concentrations by nuclear magnetic resonance spectroscopy in participants of the general population‐based PREVEND study. The study outcome was incident type 2 diabetes, defined as a fasting plasma glucose ≥7.0 mmol/L (126 mg/dl); a random sample plasma glucose ≥11.1 mmol/L (200 mg/dl); self‐report of a physician diagnosis or the use of glucose‐lowering medications based on a central pharmacy registration. Associations of plasma creatine with type 2 diabetes were quantified using Cox proportional hazards models and were adjusted for potential confounders. RESULTS: We included 4735 participants aged 52 ± 11 years, of whom 49% were male. Mean plasma creatine concentrations were 36.7 ± 17.6 µmol/L, with lower concentrations in males than in females (30.4 ± 15.1 µmol/L vs. 42.7 ± 17.7 µmol/L; p for difference <.001). During 7.3 [6.2–7.7] years of follow‐up, 235 (5.4%) participants developed type 2 diabetes. Higher plasma creatine concentrations were associated with an increased risk of incident type 2 diabetes (HR per SD change: 1.27 [95% CI: 1.11–1.44]; p < .001), independent of potential confounders. This association was strongly modified by sex (p interaction <.001). Higher plasma creatine was associated with an increased risk of incident type 2 diabetes in males (HR: 1.40 [1.17–1.67]; p < .001), but not in females (HR: 1.10 [0.90–1.34]; p = .37). CONCLUSION: Fasting plasma creatine concentrations are lower in males than in females. Higher plasma creatine is associated with an increased risk of type 2 diabetes in males.
format Online
Article
Text
id pubmed-8048485
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80484852021-04-16 Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study Post, Adrian Groothof, Dion Schutten, Joëlle C. Flores‐Guerrero, Jose L. Swarte, J. Casper Douwes, Rianne M. Kema, Ido P. de Boer, Rudolf A. Garcia, Erwin Connelly, Marge A. Wallimann, Theo Dullaart, Robin P. F. Franssen, Casper F. M. Bakker, Stephan J. L. Clin Endocrinol (Oxf) ORIGINAL ARTICLES BACKGROUND: Type 2 diabetes is associated with both impaired insulin action at target tissues and impaired insulin secretion in pancreatic beta cells. Mitochondrial dysfunction may play a role in both insulin resistance and impaired insulin secretion. Plasma creatine has been proposed as a potential marker for mitochondrial dysfunction. We aimed to investigate the association between plasma creatine and incident type 2 diabetes. METHODS: We measured fasting plasma creatine concentrations by nuclear magnetic resonance spectroscopy in participants of the general population‐based PREVEND study. The study outcome was incident type 2 diabetes, defined as a fasting plasma glucose ≥7.0 mmol/L (126 mg/dl); a random sample plasma glucose ≥11.1 mmol/L (200 mg/dl); self‐report of a physician diagnosis or the use of glucose‐lowering medications based on a central pharmacy registration. Associations of plasma creatine with type 2 diabetes were quantified using Cox proportional hazards models and were adjusted for potential confounders. RESULTS: We included 4735 participants aged 52 ± 11 years, of whom 49% were male. Mean plasma creatine concentrations were 36.7 ± 17.6 µmol/L, with lower concentrations in males than in females (30.4 ± 15.1 µmol/L vs. 42.7 ± 17.7 µmol/L; p for difference <.001). During 7.3 [6.2–7.7] years of follow‐up, 235 (5.4%) participants developed type 2 diabetes. Higher plasma creatine concentrations were associated with an increased risk of incident type 2 diabetes (HR per SD change: 1.27 [95% CI: 1.11–1.44]; p < .001), independent of potential confounders. This association was strongly modified by sex (p interaction <.001). Higher plasma creatine was associated with an increased risk of incident type 2 diabetes in males (HR: 1.40 [1.17–1.67]; p < .001), but not in females (HR: 1.10 [0.90–1.34]; p = .37). CONCLUSION: Fasting plasma creatine concentrations are lower in males than in females. Higher plasma creatine is associated with an increased risk of type 2 diabetes in males. John Wiley and Sons Inc. 2021-01-10 2021-04 /pmc/articles/PMC8048485/ /pubmed/33348429 http://dx.doi.org/10.1111/cen.14396 Text en © 2021 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle ORIGINAL ARTICLES
Post, Adrian
Groothof, Dion
Schutten, Joëlle C.
Flores‐Guerrero, Jose L.
Swarte, J. Casper
Douwes, Rianne M.
Kema, Ido P.
de Boer, Rudolf A.
Garcia, Erwin
Connelly, Marge A.
Wallimann, Theo
Dullaart, Robin P. F.
Franssen, Casper F. M.
Bakker, Stephan J. L.
Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study
title Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study
title_full Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study
title_fullStr Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study
title_full_unstemmed Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study
title_short Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study
title_sort plasma creatine and incident type 2 diabetes in a general population‐based cohort: the prevend study
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048485/
https://www.ncbi.nlm.nih.gov/pubmed/33348429
http://dx.doi.org/10.1111/cen.14396
work_keys_str_mv AT postadrian plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT groothofdion plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT schuttenjoellec plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT floresguerrerojosel plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT swartejcasper plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT douwesriannem plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT kemaidop plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT deboerrudolfa plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT garciaerwin plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT connellymargea plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT wallimanntheo plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT dullaartrobinpf plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT franssencasperfm plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy
AT bakkerstephanjl plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy